ImmuPharma PLC on Thursday announced ‘new discoveries’ regarding the mechanism of action of its P140 autoimmune technology platform.
As a result, shares in ImmuPharma were up 1.6% at 3.41 pence late on Thursday afternoon in London.
These discoveries, the London-based specialist drug discovery and development company said, provide for the first time direct evidence of a major key hypothesis of the unique MOA of P140.
ImmuPharma also said that P140 has been found not to block or reduce the body’s ability to mount a specific immune response, unlike ‘the most advanced therapies currently available’ to treat autoimmune diseases.
Finally, the findings ‘confirm P140’s potential as a safe and effective treatment for patients suffering from systemic lupus erythematosus’, the firm said.
ImmuPharma said the findings are from a new preclinical study designed by ImmuPharma Biotech’s team, and will allow the company ‘to further expand its intellectual property portfolio, with additional new patents, strengthening [P140’s] commercial viability’.
The company said that detailed data from the study will be released in due course.
Chief Executive Officer Tim McCarthy commented: ‘These stunning results clearly demonstrate the unique MOA of P140 and this data adds significantly to our ongoing discussions with potential partners and our objective to secure the optimum deal[s] for our shareholders.’
Copyright 2025 Alliance News Ltd. All Rights Reserved.
